At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SHPH Shuttle Pharmaceuticals Inc
Market Closed 12-20 16:00:00 EST
0.6401
-0.0399
-5.87%
盘后0.6110
-0.0291-4.55%
19:58 EST
High0.6943
Low0.6052
Vol120.82K
Open0.6340
D1 Closing0.6800
Amplitude13.10%
Mkt Cap2.35M
Tradable Cap1.54M
Total Shares3.66M
T/O77.70K
T/O Rate5.01%
Tradable Shares2.41M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Shuttle Pharmaceuticals enters into sponsored research agreement with UCSF
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients With Glioblastoma as Uva Cancer Center Doses Its First Patient
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas, SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers. The company was founded in 2012 and is based in Rockville, Maryland.